Abstract：【Objective】To investigate the clinical efficacy of different doses of Tigrillo in patients with acute myocardial infarction (AMI) who underwent percutaneous coronary intervention (PCI) for reperfusion.【Methods】A total of 64 AMI patients who underwent PCI surgery Xianyang Hospital of Yan'an University from April 2020 to November 2021 were selected and divided into an observation group and a control group based on different treatment methods,with 32 patients in each group. Comparison of the two groups before and after treatment was conducted including platelet function [Platelet aggregation rate,platelet count,enzyme membrane glycoprotein 63 (CD63) α Granular membrane glycoprotein 62p (CD62p)],coronary artery blood flow parameters [Peak systolic blood flow (SPV),peak diastolic blood flow (DPV),coronary flow reserve (CFVR)],myocardial injury indicators[Ischemic modified albumin (IMA),cardiac troponin I (cTnI),myoglobin (Mb),creatine kinase isoenzyme (CK-MB) ],inflammatory factors [Hypersensitivity C-reactive protein (hs-CRP),intercellular adhesion molecule-1 (ICAM-1),macrophage derived chemokine (MDC),interleukin-10 (IL-10)],and the incidence of adverse reactions after treatment.【Results】After treatment,the platelet aggregation rate,platelet count,CD63,and CD62p in both groups of patients were lower than before treatment,and the observation group was lower than the control group (P<0.05); The DPV,SPV,and CFVR of both groups of patients were higher than before treatment,and the observation group was higher than the control group (P<0.05); The levels of IMA,cTnI,Mb,and CK-MB in both groups of patients were lower than before treatment,and the observation group was lower than the control group (P<0.05); The levels of hs-CRP,ICAM-1,MDC,and IL-10 in both groups were lower than before treatment,and the observation group was lower than the control group (P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the observation group and the control group (P>0.05).【Conclusion】The treatment of AMI patients with load dose Tigrillo can improve platelet function,coronary artery blood flow,alleviate myocardial injury,and reduce the expression level of inflammatory factors in patients with reperfusion after PCI,which is of great significance for improving patient prognosis.
张会琴, 王智刚, 王小妮. 不同剂量替格瑞洛对急性心肌梗死行PCI治疗后再缺血患者的临床疗效[J]. 医学临床研究, 2023, 40(8): 1214-1217.
ZHANG Hui-qin, WANG Zhi-gang, WANG Xiao-ni. Application of Different Doses of Tigrillo in Patients with Acute Myocardial Infarction after Percutaneous Coronary Intervention with Reischemia. JOURNAL OF CLINICAL RESEARCH, 2023, 40(8): 1214-1217.
2023, Vol. 40 
